Recent Articles from GlobeNewswire

PASCAGOULA, Miss., March 03, 2026 (GLOBE NEWSWIRE) -- HII’s (NYSE: HII) Ingalls Shipbuilding division authenticated the keel today for the future USS Philadelphia (LPD 32), a Flight II San Antonio-class amphibious transport dock ship.

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Varonis (VRNS) To Contact Him Directly To Discuss Their Options

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Tennant (TNC) To Contact Him Directly To Discuss Their Options

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Regencell Bioscience Holdings Limited (NASDAQ:RGC) and Camping World Holdings, Inc. (NYSE:CWH). Our investigations concern whether these companies have violated the federal securities laws and/or engaged in other unlawful business practices. Additional information about each case can be found at the link provided.

ROAD TOWN, British Virgin Islands, March 03, 2026 (GLOBE NEWSWIRE) --  Aura Minerals Inc. (Nasdaq: AUGO) (B3: AURA33) (“Aura” or the “Company”) announced today that its issuer credit rating was upgraded by S&P Global Ratings from ‘B+’ to ‘BB-’, with stable outlook and, on national scale, S&P upgraded Aura’s Brazilian National Scale rating from ‘brAA’ to ‘brAA+’ and revised the outlook from positive to stable. The rating on the debentures issued by Aura Almas Mineração S.A. (“Aura Almas”) were also raised from ‘brAA’ to ‘brAA+’.

The $750 million investment marks the first major stadium development in Chicago in more than three decades

VeeaVision enables cybersecure Agentic AI to enhance productivity, privacy, safety, and operational resilience across enterprise environments

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Aardvark Therapeutics, Inc. (“Aardvark” or the “Company”) (NASDAQ: AARD). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Brookfield Asset Management Ltd. (NYSE: BAM) (TSX: BAM) (“Brookfield”) announced today that it has established a commercial paper program on a private placement basis. Under the program, Brookfield may issue unsecured commercial paper notes (the “notes”) up to a maximum aggregate amount outstanding at any time of $1 billion. The program is expected to further diversify and strengthen Brookfield’s balance sheet by providing another source of short-term capital. The proceeds from the issuance of any notes will be used for general corporate purposes.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FS KKR Capital Corp. (“FSK”) (NYSE: FSK).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

CINCINNATI, March 03, 2026 (GLOBE NEWSWIRE) -- Quipt Home Medical Corp. (the “Company”) (NASDAQ: QIPT; TSX: QIPT)‎, a U.S. based home medical equipment provider, focused on end-to-end respiratory care, today announced the voting results from its special meeting of holders (the “Shareholders”) of common shares (the “Shares”) of the Company held on March 3, 2026 (the “Meeting”) in Sarasota, Florida. The Shareholders voted to approve the special resolution (the “Arrangement Resolution”) approving the plan of arrangement under the Business Corporations Act (British Columbia), involving, among other things, the acquisition by affiliates of Kingswood Capital Management, L.P. and Forager Capital Management, LLC of all of the issued and outstanding Shares (the “Arrangement”) for cash consideration of US$3.65 per Share.

PARSIPPANY, N.J. and CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and funds managed by Blackstone Life Sciences (“BXLS”) today announced a $400 million strategic funding agreement spread across four years to support the continued clinical development of duvakitug. Additionally, under the terms of the agreement, BXLS will be eligible for regulatory and commercial milestones as well as royalties on duvakitug worldwide sales.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) today announced that its 2026 Annual Meeting of Stockholders will be held virtually on June 8, 2026, at 12:00 pm ET. The record date for the meeting is April 17, 2026. Information on the virtual meeting will be included in the 2026 proxy statement.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Apollo Global Management, Inc. (“Apollo” or the “Company”) (NYSE: APO).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PROCEPT BioRobotics Corporation (“Procept” or the “Company”) (NASDAQ: PRCT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Sunrun Inc. (“Sunrun” or the “Company”) (NASDAQ: RUN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Walker & Dunlop, Inc. (“Walker & Dunlop” or the “Company”) (NYSE: WD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Fulgent Genetics, Inc. (“Fulgent” or the “Company”) (NASDAQ: FLGT). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eos Energy Enterprises, Inc.  (“Eos” or the “Company”) (NASDAQ: EOSE). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ambarella, Inc. (“Ambarella” or the “Company”) (NASDAQ: AMBA).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Franklin BSP Realty Trust, Inc. (“Franklin” or the “Company”) (NYSE: FBRT).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased. 

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Duolingo, Inc. (“Duolingo” or the “Company”) (NASDAQ: DUOL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of KKR & Co. Inc. (“KKR” or the “Company”) (NYSE: KKR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Xponential Fitness, Inc. (“Xpontential” or the “Company”) (NYSE: XPOF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of February 28, 2026

SAN FRANCISCO, March 03, 2026 (GLOBE NEWSWIRE) -- Olema Pharmaceuticals, Inc. (“Olema” or “Olema Oncology”, Nasdaq: OLMA), a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for breast cancer and beyond, today announced that the Company granted stock options to four new employees to purchase an aggregate of 205,000 shares of the Company's common stock, effective as of March 2, 2026. These awards were approved by the Compensation Committee of Olema’s Board of Directors and granted under the Company's 2022 Inducement Plan as an inducement material to the new employees entering into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).

FRIENDSWOOD, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that it will host a grand opening celebration for its new corporate headquarters on Tuesday, March 24, 2026, at 3:00 p.m. Central time. The event will take place at the Company’s new campus located at 1500 West Parkwood Avenue in Friendswood, Texas, and will bring together employees, community partners and other invited guests to commemorate the completion of the purpose-built facility.

LEIDEN, Netherlands & CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies based on its proprietary ADAR-mediated Axiomer™ RNA editing technology platform, today announced that company management will present at the Citizens Life Sciences Conference on Wednesday, March 11, 2026 at 3:25pm ET.

DEER PARK, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter and full year 2025 financial results on Thursday, March 19, 2026. Management will host a conference call and live audio webcast to discuss the results at 4:30 p.m. ET (3:30 p.m. CT).

EDMONTON, Alberta, March 03, 2026 (GLOBE NEWSWIRE) -- The Board of Directors for Capital Power Corporation (“Capital Power”) (TSX: CPX) declared a dividend of $0.6910 per share on the outstanding common shares for the quarter ending March 31, 2026. The dividend is payable on April 30, 2026 to shareholders of record at the close of business on March 31, 2026.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of First Solar, Inc. (“First Solar” or the “Company”) (NASDAQ: FSLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Driven Brands Holdings Inc. (“Driven” or the “Company”) (NASDAQ: DRVN). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of C3.ai, Inc. (“C3” or the “Company”) (NYSE: AI).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Camping World Holdings, Inc. (“Camping World” or the “Company”) (NYSE: CWH).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Oddity Tech Ltd. (“Oddity” or the “Company”) (NASDAQ: ODD).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Company plans to enter into capped call transactions and repurchase shares of its common stock to opportunistically create value for shareholders

BASEL, Switzerland and VANCOUVER, British Columbia, March 03, 2026 (GLOBE NEWSWIRE) -- Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant Sciences Ltd. (Nasdaq: ROIV), and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, today announced that they have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.

BASEL, Switzerland and LONDON and NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Roivant (Nasdaq: ROIV) today announced that Genevant Sciences, a leading nucleic acid delivery company with world-class platforms and a robust lipid nanoparticle (LNP) patent portfolio and a subsidiary of Roivant, and Arbutus Biopharma Corporation (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on infectious disease, have entered into a $2.25 billion global settlement with Moderna, Inc. to resolve all U.S. and international enforcement actions involving Moderna’s unauthorized use of Genevant’s and Arbutus’ LNP delivery technology in its COVID-19 vaccines, including Spikevax®.

LITTLE ROCK, Ark., March 03, 2026 (GLOBE NEWSWIRE) -- Uniti Group Inc. (“Uniti”) (Nasdaq: UNIT) announced today that its Chief Financial Officer and Treasurer, Paul Bullington, and Senior Vice President, Investor Relations & Treasury, Bill DiTullio, are scheduled to participate at the Deutsche Bank 34th Annual Media, Internet & Telecom Conference on March 10, 2026 in Palm Beach, FL.

TULSA, Okla., March 03, 2026 (GLOBE NEWSWIRE) -- ONEOK, Inc. (NYSE: OKE) will hold its 2026 annual meeting of shareholders virtually on May 20, 2026, at 9 a.m. Central Time.

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today provided an update on the potential spin-off of its biopharma operations and reported financial results for the fourth quarter and year ended Dec. 31, 2025.

SMITHFIELD, Va., March 03, 2026 (GLOBE NEWSWIRE) -- Smithfield Foods, Inc. (Nasdaq: SFD), an American food company and an industry leader in value-added packaged meats and fresh pork, today announced that its financial results for the fiscal 2025 fourth quarter and full year will be released before market open on Tuesday, March 24, 2026. The company will host a conference call at 9:00 a.m. Eastern Time to discuss the financial results. A live audio webcast of the conference call, together with related materials, will be available online at investors.smithfieldfoods.com.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Alight, Inc. (“Alight” or the “Company”) (NYSE: ALIT).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Gossamer Bio, Inc. (“Gossamer” or the “Company”) (NASDAQ: GOSS). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of FMC Corporation (“FMC” or the “Company”) (NYSE: FMC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Jefferies Financial Group Inc. (“Jefferies” or the “Company”) (NYSE: JEF). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Tennant Company (“Tennant” or the “Company”) (NYSE: TNC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Stellantis N.V. (“Stellantis” or the “Company”) (NYSE: STLA). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of GrafTech International Ltd. (“GrafTech” or the “Company”) (NYSE: EAF).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

SAXONBURG, Pa., March 03, 2026 (GLOBE NEWSWIRE) -- Coherent Corp. (NYSE: COHR), a global leader in photonics, today announced that its executives and technology leaders will play a prominent role at OFC 2026, taking place March 15–19 in Los Angeles, California. 

ZUG, Switzerland, March 3, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (Oculis), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in ophthalmology and neuro-ophthalmology, today announced results for the fourth quarter and full year ended December 31, 2025, and provided an overview of the Company’s progress.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Teladoc Health, Inc. (NYSE: TDOC), the global leader in virtual care, announced today that Chuck Divita, chief executive officer, will participate in the Barclays 28th Annual Global Healthcare Conference in Miami on March 10th, 2026, at 1:00 p.m. ET. A live audio webcast and replay of the presentation will be available at http://ir.teladochealth.com/news-and-events/events-and-presentations/. 

ROLLING MEADOWS, Ill., March 03, 2026 (GLOBE NEWSWIRE) -- RYTHM, Inc. (Nasdaq: RYM) (“RYTHM” or the “Company”), which delivers well-being to consumers through its portfolio of iconic brands and hemp-derived THC products including Señorita THC Margaritas, incredibles, and RYTHM Beverages, today announced financial results for the fourth quarter and full year ended December 31, 2025.

HOUSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Epsilon Energy Ltd. (“Epsilon” or the “Company”) (NASDAQ: EPSN) today announced that its Board of Directors has declared a dividend of $0.0625 per share of common stock (annualized $0.25/sh) to the stock holders of record at the close of business on March 13, 2026, payable on March 31, 2026. All dividends paid by the Company are “eligible dividends” as defined in subsection 89(1) of the Income Tax Act (Canada), unless indicated otherwise.

Singapore, March 03, 2026 (GLOBE NEWSWIRE) -- Orangekloud Technology Inc. (Nasdaq: ORKT) (“Orangekloud” or “the Company”), a Singapore-based technology company offering the eMOBIQ® No-Code platform for the development of mobile applications and SaaS subscription-based ISV Solutions, today announced an update on the Proposed Merger Transaction with Orbis Technology Limited (“Orbis”).

HOUSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Orion Group Holdings, Inc. (NYSE: ORN) (the “Company” or “Orion”), a leading specialty construction company, today reported its financial results for the fourth quarter and full year ended December 31, 2025.

Total Revenue Growth of 25.3% Year Over Year in the Fourth Quarter

Itron’s Cellular 500G and 500W Modules Operate Under UtilityIQ® Application Suite for the First Time, Enabling a Unified Headend Across Electric, Gas and Water Deployments

BOSTON, March 03, 2026 (GLOBE NEWSWIRE) -- Rapid7, Inc. (NASDAQ: RPD), a global leader in AI-powered managed cybersecurity operations, today announced that the company will be attending the Stifel 2026 NYC Technology One-on-One Conference on Tuesday, March 10, 2026.

Full Year 2025 Revenue Growth of 2.5%; Year-Over-Year Revenue Growth on a Constant Currency Basis of 3.9% 

LATHAM, N.Y., March 03, 2026 (GLOBE NEWSWIRE) -- Latham Group, Inc. (Nasdaq: SWIM), the largest designer, manufacturer, and marketer of in-ground residential swimming pools in North America, Australia, and New Zealand, today announced that it has acquired Freedom Pools, a fiberglass pool manufacturer and installer operating in Australia and New Zealand. The transaction was completed on February 26, 2026.

Delivered 9th consecutive year of profitability with net income of $76.7 million, or 10.8% margin

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Cibus, Inc. (Nasdaq: CBUS), a leading agricultural technology company that develops and licenses plant traits to seed companies, today announced that the company will report fourth quarter 2025 financial results on Tuesday, March 17, 2026. Cibus’ management team will host a conference call and audio webcast at 4:30 p.m. ET on that day to discuss the financial results and other company updates.

Fourth Quarter 2025 Financial Highlights:

Shared 12-month clinical results of ongoing UP421 type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression are safe and well-tolerated, evade detection by the immune system, and continue to function one year post-transplant

SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida.

SuRo Capital to Ring The NASDAQ Stock Market Opening Bell

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of EPAM Systems, Inc. (“EPAM” or the “Company”) (NYSE: EPAM).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of The Chemours Company (“Chemours” or the “Company”) (NYSE: CC). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

NEW YORK, March 03, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of DNOW Inc. (“DNOW” or the “Company”) (NYSE: DNOW).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Melville, NY, March 03, 2026 (GLOBE NEWSWIRE) -- Canon U.S.A., Inc., a leader in digital imaging solutions, proudly announces that it has been recognized by Keypoint Intelligence with the 2026 A3 Line of the Year Award, in addition to receiving several 2026 Pick Awards for the uniFLOW Online solution and devices across the imageCLASS X and imageFORCE product portfolios.

Pipeline infrastructure will support regional economic development opportunities and expand access to natural gas for local families and businesses

THE WOODLANDS, Texas, March 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in an upcoming fireside chat at the 2026 Leerink Partners Global Healthcare Conference in Miami on Wednesday, March 11, at 10:00 a.m.

NEW YORK and WALTHAM, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced that it granted equity awards on March 2, 2026, to three newly-hired, non-executive employees. The inducement grants were approved by the Company's independent Compensation Committee and were made as material inducements to acceptance of employment with Dianthus in accordance with Nasdaq Listing Rule 5635(c)(4).